SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors
- PMID: 11543951
- DOI: 10.1016/s0361-9230(01)00550-0
SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors
Abstract
Recent work suggests that opioids which combine mu agonist and delta antagonist activity may be non-addicting antinociceptive agents. SoRI 9409 (5'-(4-Chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5alpha-epoxypyrido-[2',3':6,7]morphinan) is a naltrexone-derived non-peptide ligand which demonstrates partial mu and kappa agonist activity and antagonist activity at delta receptors. Chronic administration of SoRI 9409 to mice failed to produce tolerance to its antinociceptive effect and SoRI 9409 produced less withdrawal signs than naloxone in acute and chronic morphine dependence models. To further characterize SoRI 9409 we determined its effects in the guanosine 5'-O-(3-[35S]thio)-triphosphate binding assay. SoRI 9409 demonstrated no agonist activity at cloned mu delta, or kappa receptors. Other experiments demonstrated that SoRI 9409 was a potent and selective delta antagonist (K(i) = 0.08 nM) which acted also as an antagonist at mu and kappa receptors. Its profile of activity resembled that of naltrindole (NTI). Viewed collectively, the in vitro data reported here predict that SoRI 9409 should be a mu antagonist in vivo, which is not observed. Resolving these discrepant findings will require additional research.
Similar articles
-
In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.J Pharmacol Exp Ther. 2001 May;297(2):597-605. J Pharmacol Exp Ther. 2001. PMID: 11303048
-
The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6. Naunyn Schmiedebergs Arch Pharmacol. 2007. PMID: 17340127
-
Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.J Comp Neurol. 1997 Oct 6;386(4):562-72. doi: 10.1002/(sici)1096-9861(19971006)386:4<562::aid-cne4>3.0.co;2-0. J Comp Neurol. 1997. PMID: 9378852
-
Pharmacological characterization of human kappa/mu opioid receptor chimeras that retain high affinity for dynorphin A.Curr Top Med Chem. 2005;5(3):303-13. doi: 10.2174/1568026053544542. Curr Top Med Chem. 2005. PMID: 15857313 Review.
-
Evidence for the existence of the beta-endorphin-sensitive "epsilon-opioid receptor" in the brain: the mechanisms of epsilon-mediated antinociception.Jpn J Pharmacol. 1998 Mar;76(3):233-53. doi: 10.1254/jjp.76.233. Jpn J Pharmacol. 1998. PMID: 9593217 Review.
Cited by
-
The delta opioid receptor antagonist, SoRI-9409, decreases yohimbine stress-induced reinstatement of ethanol-seeking.Addict Biol. 2012 Mar;17(2):224-34. doi: 10.1111/j.1369-1600.2010.00295.x. Epub 2011 Feb 11. Addict Biol. 2012. PMID: 21309957 Free PMC article.
-
Pharmacological traits of delta opioid receptors: pitfalls or opportunities?Psychopharmacology (Berl). 2013 Jul;228(1):1-18. doi: 10.1007/s00213-013-3129-2. Epub 2013 May 7. Psychopharmacology (Berl). 2013. PMID: 23649885 Free PMC article. Review.
-
Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.Br J Pharmacol. 2012 May;166(1):309-26. doi: 10.1111/j.1476-5381.2011.01750.x. Br J Pharmacol. 2012. PMID: 22023056 Free PMC article.
-
Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.AAPS J. 2006 Mar 10;8(1):E118-25. doi: 10.1208/aapsj080114. AAPS J. 2006. PMID: 16584118 Free PMC article. Review.
-
The role of δ-opioid receptors in learning and memory underlying the development of addiction.Br J Pharmacol. 2015 Jan;172(2):297-310. doi: 10.1111/bph.12618. Epub 2014 Jul 1. Br J Pharmacol. 2015. PMID: 24641428 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
